Apremilast is a relatively new therapy for the treatment of moderate to severe plaque
psoriasis in adults. While this medication is considered safe with a very low risk of serious …

This real‐world study at a single academic center retrospectively examined the drug survival
of apremilast for patients with psoriasis. Retrospective information was extracted from the …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Introduction: Psoriasis is a common skin disorder characterized by chronic inflammatory
lesions that are frequently vexing for patients and difficult for physicians to treat. Although …

Objectives The aim of this paper is to present our personal as well as literature-sourced real-
world evidenced on apremilast use in psoriasis patients with serious baseline comorbidities …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

ABSTRACT Introduction: Psoriasis (PSo) is a chronic inflammatory skin disease associated
with co-morbidities such as hypertension, diabetes, dyslipidemia and metabolic syndrome. It …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …

Apremilast (Otezla®) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …